One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn, NY, USA.
Government Kilpauk Medical College, Chennai, Tamil Nadu, India.
J Natl Cancer Inst. 2024 Jul 1;116(7):1026-1034. doi: 10.1093/jnci/djae051.
Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic review, we assessed all randomized controlled trials (RCTs) investigating dietary interventions for cancer patients, examining the range of interventions, endpoints, patient populations, and results.
This systematic review identified all RCTs conducted before January 2023 testing dietary interventions in patients with cancer. Assessed outcomes included quality of life, functional outcomes, clinical cancer measurements (eg, progression-free survival, response rates), overall survival, and translational endpoints (eg, inflammatory markers).
In total, 252 RCTs were identified involving 31 067 patients. The median sample size was 71 (interquartile range 41 to 118), and 80 (32%) studies had a sample size greater than 100. Most trials (n = 184, 73%) were conducted in the adjuvant setting. Weight or body composition and translational endpoints were the most common primary endpoints (n = 64, 25%; n = 52, 21%, respectively). Direct cancer measurements and overall survival were primary endpoints in 20 (8%) and 7 (3%) studies, respectively. Eight trials with a primary endpoint of cancer measurement (40%) met their endpoint. Large trials in colon (n = 1429), breast (n = 3088), and prostate cancer (n = 478) each showed no effect of dietary interventions on endpoints measuring cancer.
Most RCTs of dietary interventions in cancer are small and measure nonclinical endpoints. Although only a small number of large RCTs have been conducted to date, these trials have not shown an improvement in cancer outcomes. Currently, there is limited evidence to support dietary interventions as a therapeutic tool in cancer care.
先前针对饮食对癌症结局影响的系统评价主要集中在特定的饮食干预措施上。在本次系统评价中,我们评估了所有针对癌症患者的饮食干预进行的随机对照试验(RCT),考察了干预措施的范围、终点、患者人群和结果。
本系统评价确定了截至 2023 年 1 月,所有测试癌症患者饮食干预的 RCT。评估的结果包括生活质量、功能结局、临床癌症测量(例如无进展生存期、缓解率)、总生存期和转化终点(例如炎症标志物)。
共确定了 252 项涉及 31067 名患者的 RCT。中位数样本量为 71(四分位距 41 至 118),80 项研究(32%)的样本量大于 100。大多数试验(n=184,73%)在辅助治疗环境中进行。体重或身体成分和转化终点是最常见的主要终点(n=64,25%;n=52,21%)。直接癌症测量和总生存期分别是 20 项(8%)和 7 项(3%)研究的主要终点。8 项以癌症测量为主要终点的试验(40%)达到了其终点。在结肠癌(n=1429)、乳腺癌(n=3088)和前列腺癌(n=478)的大型试验中,饮食干预对测量癌症的终点均无影响。
大多数癌症饮食干预的 RCT 规模较小,测量非临床终点。尽管迄今为止仅进行了少数大型 RCT,但这些试验并未显示癌症结局的改善。目前,支持饮食干预作为癌症治疗工具的证据有限。